Masco Corporation (MAS) emerges as a top long-term growth and value stock in the bio-tech market. Their financial performance has seen significant growth, which alongside strong margins, has driven the stock price to an all-time high of $83.6, with
Barclays even raising the price target to $92. Despite some underperforming days, the stock remains a strong consideration for investor portfolios. The corporation recently completed its
Kichler Lighting sale, a strategic move aimed to streamline its focus and unlock additional value. This effort, along with the inherent investment value of MAS, has attracted several big buyers, including Sanctuary Advisors and Mackenzie Financial Corp, further validating the stock's worth. MAS has also surpassed Q2 earnings estimates and the analysts anticipate a bullish course for the stock's performance. However, Masco's president and CEO
Keith Allman sold over 1.2 million shares, leading to some cautious speculation. Nevertheless, ongoing proactive strategies and strong financial performances suggest a potential upside.
Masco Corporation MAS News Analytics from Fri, 30 Dec 2011 08:00:00 GMT to Sat, 12 Oct 2024 10:48:01 GMT -
Rating 7
- Innovation 3
- Information 6
- Rumor 2
